A U.S. judge said on Tuesday that Novo Nordisk must face part of a lawsuit accusing it of defrauding shareholders about a clinical trial for its weight loss and diabetes treatment CagriSema. Novo Nordisk’s American depositary receipts fell 17.8% on …
Source: Claims Journal